WO2018216823A1 - Dérivés d'alpha-amino-amide - Google Patents

Dérivés d'alpha-amino-amide Download PDF

Info

Publication number
WO2018216823A1
WO2018216823A1 PCT/JP2018/021101 JP2018021101W WO2018216823A1 WO 2018216823 A1 WO2018216823 A1 WO 2018216823A1 JP 2018021101 W JP2018021101 W JP 2018021101W WO 2018216823 A1 WO2018216823 A1 WO 2018216823A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
amino
phenyl
hydrochloride
hydroxy
Prior art date
Application number
PCT/JP2018/021101
Other languages
English (en)
Inventor
Hajime Takashima
Fumihito Ushiyama
Yousuke Yamada
Yohei Matsuda
Takashi Yoshizumi
Chunhae KIM
Junya Yamagishi
Alba Teresa Macias ARRATE
Stephen David ROUGHLEY
Sean Mckenna
David Lee Walmsley
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Publication of WO2018216823A1 publication Critical patent/WO2018216823A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • This invention relates to novel alpha-amino amide derivatives or salts thereof, which exhibit an activity for inhibiting uridyldiphospho(UDP)-3-0-acyl-N-acetylglucosamine deacetylase (LpxC) and antimicrobial pharmaceuticals comprising the same.
  • Gram-negative bacteria have an outer membrane composed of a lipid bilayer inexistent in gram-positive bacteria, and thus are more resistant to drugs, as compared with gram-positive bacteria, due to the problem of drug permeability. Gram-negative bacteria are also known to have a plurality of drug efflux proteins, which are known to be involved in drug resistance (Non-Patent Document 1). Furthermore, lipopolysaccharide (LPS), one of the main constituents of the outer membrane, is involved in toxicity as an endotoxin.
  • LPS lipopolysaccharide
  • Pseudomonas aeruginosa Among gram-negative bacteria, Pseudomonas aeruginosa, in particular, has a strong tendency to show natural resistance to various antimicrobial agents. In recent years,
  • Non-Patent Document 2 Pseudomonas aeruginosa strains, which has gained resistance to carbapenem drugs, quinolone drugs or aminoglycoside drugs, has been clinically isolated in medical settings. Moreover, multi-drug resistant Pseudomonas aeruginosa which has obtained resistance to all of these three types of drugs has been isolated (Non-Patent Document 3). Emergence of multi-drug resistant Pseudomonas aeruginosa has become a major healthcare problem worldwide, because there have been few useful therapeutic drugs. Hence, there is a keen demand for the development of a drug having a novel mechanism of action.
  • UDP-3-O-acyl-N-acetylglucosamine deacetylase is an enzyme in charge of the synthesis of lipid A (hydrophobic anchor of LPS which is the constituent of the outer membrane).
  • Lipid A biosynthesis consists of reactions in ten stages, and LpxC catalyzes the second stage of the biosynthesis reactions to remove the acetyl group of UDP-3-O-acyl-N- acetylglucosamine (Non-Patent Document 4).
  • Lipid A is a component essential for the formation of the outer membrane, and is consequently indispensable for the survival of gram- negative bacteria (Non-Patent Document 5).
  • LpxC is a rate-determining enzyme in the process of lipid A biosynthesis, and is an indispensable enzyme for lipid A biosynthesis.
  • a drug inhibiting the activity of LpxC is highly expected to be an antimicrobial agent effective against gram-negative bacteria including Pseudomonas aeruginosa, particularly against drug resistant Pseudomonas aeruginosa and other gram-negative bacteria, because such a drug has a mechanism of action different from those of conventional drugs.
  • LpxC has been the focus of several pharmaceutical drug development programs over the last decade. LpxC has the catalytic zinc ion in its active site and many of the potent LpxC inhibitors identified so far contain a zinc-binding hydroxamic acid group.
  • Patent Document 1 International Publication 15/085238 pamphlet.
  • Non-Patent Document 1 Antimicrobial Resistance (2002) Mar 1, 34, pp. 634-640.
  • Non-Patent Document 2 J. Antimicrob. Chemother. (2003) Jan 14, 51, pp. 347-352.
  • Non-Patent Document 3 J Hosp Med. (2013) Sep 10, 8, pp. 559-563.
  • Non-Patent Document 4 J. Biol. Chem. (1995) Dec 22, 270, pp. 30384-30391.
  • Non-Patent Document 5 J. Bacteriol. (1987), 169, pp. 5408-5415.
  • Non-Patent Document 6 Cold Spring Harb Perspect Med. (2016), July 1 ; 6(7), a025304.
  • Non-Patent Document 7 Curr Top Med Chem. (2016) 16(21), pp. 2379-2430.
  • An object of the present invention is to find novel compounds that do not contain a hydroxamic acid group and inhibit LpxC or pharmaceutically acceptable salts thereof, and provide new pharmaceutical drugs that exhibit antimicrobial activity against gram-negative bacteria including Pseudomonas aeruginosa and their drug resistant strains and that are useful in treating bacterial infections.
  • the present inventors have conducted in-depth studies in an attempt to find out a compound having LpxC-inhibiting activity. As a result, they have found that a non-hydroxamic acid compound represented by the following general formula [1] or a pharmaceutically acceptable salt thereof attains the above object. Based on this finding, they have accomplished the present invention.
  • the present invention will be described below.
  • the present invention provides (1) A compound represented by the following general formula [1] or a pharmaceutically acceptable salt thereof:
  • Y represents a group selected from the following formula [3]:
  • R 1 represents a group selected from the following formula [4]:
  • L represents a bond or a C alkylene group
  • R 2 represents a phenyl group or a halogen atom
  • R 3 represents a group selected from the following formula [5] :
  • L 3 represents a C alkylene group, a C alkynylene group, -0-, -OCH2-, -CH2O-, a bond,
  • R 4 represents a group selected from the following formula [6] :
  • L 4 represents -C ⁇ C-, a CM alkylene group or a bond
  • R 5 represents a group selected from the following formula [7]
  • L 5 represents -C ⁇ C ⁇ , a CM alkylene group or a bond
  • R 6 represents a group selected from the following formula [8]:
  • L 6 represents ⁇ C ⁇ C-, a C 1-4 alkylene group or a bond
  • W represents a hydrogen atom, a halogen atom, a phenyl group, a CM hydroxyalkyl group, HOCH 2 CH 2 0- HOOC-CH2CH2- or N-morpholinomethyl group, n represents 1 or 2, and * indicates the site of the attachment of a moiety;
  • R 1 , R 3 , R 4 and R 5 are as defined in item (1).
  • R 6 is as defined in item (1)
  • a pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof according to any one of items (1) to (6);
  • An LpxC inhibitor comprising the compound or the pharmaceutically acceptable salt thereof according to any one of items (1) to (6).
  • An antimicrobial agent comprising the compound or the pharmaceutically
  • the compound or the pharmaceutically acceptable salt thereof according to the present invention has a strong LpxC-inhibiting action.
  • the compound or its pharmaceutically acceptable salt is useful as a pharmaceutical composition and as an antimicrobial agent against gram-negative bacteria.
  • n- means normal, "i-" iso, "sec-” secondary, “tert-” tertiary, “c-” cyclo, "o-" ortho, "m-” meta, and "p-" para.
  • halogen atom means a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
  • C M alkyl group refers to a straight-chain or branched-chain alkyl group having 1 to 4 carbon atoms. Its examples are a methyl group, an ethyl group, a n-propyl group, a n-butyl group, an isopropyl group, an isobutyl group, a tert-butyl group and a sec-butyl group.
  • C 2-4 alkynyl group refers to a straight-chain or branched-chain alkynyl group with 2 to 4 carbon atoms which has one or more triple bonds at any position(s) of the above-mentioned "d- 8 alkyl group”. Its examples are an ethynyl group, a 1-propynyl group, a 2-propynyl group, a 1-butynyl group and a 3-butynyl group.
  • C M hydroxyalkyl group refers to an alkyl group in which one or more of the hydrogen atoms of the above-mentioned "CM alkyl group” has been or have been substituted with a hydroxyl group or hydroxyl groups. Its examples are a hydroxymethyl group, a 1 - hydroxyethyl group, a 2-hydroxyethyl group, a 2-hydroxypropyl group, a 3-hydroxypropyl group, a 1-hydroxybutyl group, a 2-hydroxybutyl group, a 3-hydroxybutyl group and a 4- hydroxybutyl group.
  • C M alkylene group refers to a straight-chain or branched-chain alkylene group having 1 to 4 carbon atoms. Its examples are -CH 2 -, -(CH 2 ) 2 -, -(CH 2 ) 3 -, -CH 2 -CH(CH 3 , -C(CH 3 ) 2 -, -(CH 2 ) 4 -, -(CH 2 ) 2 -CH(CH 3 )-, -CH 2 -CH(CH 3 )-CH 2 - and -CH(CH 3 )-(CH 2 ) 2 -.
  • C 2- 4 alkynylene group refers to a straight-chain or branched-chain alkynylene group having 2 to 4 carbon atoms which has one or more triple bonds in the chain.
  • protecting group for an amino group include all groups usable usually as protecting groups for an amino group, and includes, for example, the groups described in P.G.M. Wuts et al., Protective Groups in Organic Synthesis, 5th Ed., 2014, John Wiley Sons, Inc.
  • the "leaving group” includes, for example, a halogen atom, a methnesulfonyloxy group, a ethanesulfonyloxy group, a isopropanesulfonyloxy group, a trifluoromethanesulfonyloxy group, benzensulfonyloxy group and a p-toluenesulfonyloxy group.
  • the "antimicrobial agent” refers to a substance which has the ability to act on bacteria, such as gram-positive bacteria or gram-negative bacteria, thereby suppressing their growth or destroying them.
  • the antimicrobial agent may be one which keeps down propagation of bacteria, or kills some of bacteria to decrease their count.
  • Examples of gram-positive bacteria are the genus Staphylococcus (Staphylococcus aureus, Staphylococcus epidermidis, etc.), the genus Streptococcus (Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus pneumoniae, etc.), and the genus Enterococcus (Enterococcus faecalis, Enterococcus faecium, etc.).
  • Staphylococcus Staphylococcus aureus, Staphylococcus epidermidis, etc.
  • the genus Streptococcus Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus pneumoniae, etc.
  • Enterococcus Enterococcus faecalis, Enterococcus faecium, etc.
  • Examples of gram-negative bacteria are the genus Pseudomonas (Pseudomonas aeruginosa, etc.), the genus Escherichia (Escherichia coli, etc.), the genus Klebsiella
  • Acinetobacter calcoaceticus, etc. the genus Legionella (Legionella pneumophila, etc.), the genus Bacteroides (Bacteroides fragilis, etc.), the genus Neisseria (Neisseria gonorrhoeae, Neisseria meningitides, etc.), the genus Moraxella (Moraxella catarrhalis, etc.), the genus Chlamydia (Chlamydia trachomatis, Chlamydia psittaci, etc.), and the genus Helicobacter (Helicobacter pylori, etc.).
  • Preferred X is a rou represented by the followin formula 2a] :
  • R 1 , R 3 , R 4 and R 5 are defined above,
  • Preferred Y is a group represented b the following formula 3a]
  • X is a group represented by the following formula [3b]:
  • Preferred R is a group represented by the following formula [4]:
  • W is a hydrogen atom, a C 1-4 hydroxyalkyl group, HOCH 2 CH 2 0- or N-morpholinomethyl group.
  • a preferred sent invention is as follows
  • the compounds represented by the formula [1] of the present invention have asymmetric carbon at alpha-carbon atom.
  • the compounds of the present invention may be used in racemic form or as a specific enantiomer.
  • the compounds represented by the following formula [10] are preferred:
  • the compounds of the present invention can exist as tautomers, stereoisomers such as geometrical isomers, and optical isomers, and the present invention includes them.
  • the present invention also includes various hydrates, solvates and polymorphic substances of the compounds of the invention and their salts.
  • the pharmaceutically acceptable salts refer to salts which are used in chemotherapy and prevention of bacterial infections.
  • Their examples are salts with acids such as formic acid, acetic acid, propionic acid, butyric acid, trifluoroacetic acid, maleic acid, tartaric acid, citric acid, stearic acid, succinic acid, ethylsuccinic acid, malonic acid, lactobionic acid, gluconic acid, glucoheptonic acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid (tosic acid), laurylsulfuric acid, malic acid, aspartic acid, glutamic acid, adipic acid, hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, hydriodic acid, nicotinic acid, oxalic
  • the compound of the present invention can be made into a medicinal preparation upon combination with one or more pharmaceutically acceptable carriers, excipients or diluents.
  • carriers, excipients and diluents include water, lactose, dextrose, fructose, sucrose, sorbitol, mannitol, polyethylene glycol, propylene glycol, starch, gum, gelatin, alginate, calcium silicate, calcium phosphate, cellulose, aqueous syrup, methyl cellulose, polyvinyl pyrrolidone, alkylparahydroxybenzosorbate, talc, magnesium stearate, stearic acid, glycerin, sesame oil, olive oil, soy oil, and various other seed oils.
  • the above carriers, excipients or diluents can be mixed, as needed, with commonly used additives such as thickeners, binders, disintegrants, pH regulators, and solvents, and can be prepared as an oral or parenteral drug, such as tablets, pills, capsules, granules, powders, liquids, emulsions, suspensions, ointments, injections, or skin patches, by a customary pharmaceutical technology.
  • the compound of the present invention can be administered intravenously, orally or parenterally to an adult patient in a dose of 10 to 5,000 mg as a single daily dose or as divided portions per day. This dose can be increased or decreased, as appropriate, according to the type of the disease to be treated, or the age, body weight, symptoms, etc. of the patient.
  • the compound of the present invention can also be used in combination with other drugs.
  • the compound of the present invention can be synthesized, for example, by methods to be shown below, but the present invention is in no way limited to these methods of
  • a compound represented by the general formula (I-A) (where R Ia -NH-R Ib is a compound represented in formula [2] defined above) is reacted with a compound represented by the general formula (I-B) (where R Ic is a hydroxyl group or a halogen atom, PG is a protecting group for an amino group, and Y is as defined above) in the presence of a condensing agent (in case R Ic is a hydroxyl group) and in the presence or absence of a base, whereby a compound represented by the general formula (I-C) can be obtained. Then, the compound represented by the general formula (I-C) is reacted under appropriate conditions in
  • a compound having a benzylpiperidine group represented in formula [2] can be synthesized in the following scheme II.
  • a compound represented by the general formula (II-A) (where W is as defined above) is reacted with a compound represented by the general formula (II-B) (where R IIa is a leaving group, PG is a protecting group for an amino group, and the other symbol is as defined above) in the presence of catalysts, such as bis(triphenylphosphine)dichloropalladium and cupper iodide, in the presence or absence of a base, and in the presence or absence of a ligand, whereby a compound represented by the general formula (II-C) (where the symbols are as defined above) can be obtained.
  • catalysts such as bis(triphenylphosphine)dichloropalladium and cupper iodide
  • a compound having the other group represented in formula [2] (a benzylidenepiperidine group substituted by R 2 , an indoline group substituted by R 3 , a 1,2,3,4-tetrahydroisoquinoline group substituted by R 4 , a lH-indol-3 -amine group substituted by R 5 or an aniline group substituted by R 6 ) can be synthesized in the same manner as scheme II by replacing the compound of the general formula (II-B) with the corresponding compound.
  • the sequence of the reaction steps can be changed as needed. If an amino group, a hydroxyl group, a formyl group, and a carboxy group are present in the compounds obtained in the respective reaction steps and their intermediates, the reactions can be performed, with the protective groups for them being removed for deprotection or being used in appropriately changed combinations.
  • examples of the base used in any of the above reactions are sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium acetate, potassium acetate, potassium hydroxide, sodium hydroxide, lithium hydroxide, sodium methoxide, potassium tert-butoxide, sodium hydride, lithium hydride, triethylamine, diisopropylethylamine, dimethylaniline, diethylaniline, pyridine, pyrrolidine, and N-methylmorpholine.
  • Examples of the catalyst are palladium acetate, palladium chloride,
  • Examples of the ligand are tri-tert-butylphosphine, tricyclohexylphosphine,
  • triphenylphosphine tritolylphosphine, tributyl phosphite, tricyclohexyl phosphite, triphenyl phosphite, 1 , 1 '-bis(diphenylphosphino)ferrocene, 2,2'-bis(diphenylphosphino)- 1 , ⁇ - binaphthyl, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl, 2-dicyclohexylphosphino- 2',4',6'-triisopropylbiphenyl, 2-(di-tert-butylphosphino)-2',4',6'-triisopropylbiphenyl, and 2- (di-tert-butylphosphino)biphenyl.
  • the solvent is not limited, if it is stable under the reaction conditions concerned, is inert, and does not impede the reaction.
  • the solvent are polar solvents (e.g., water and alcoholic solvents such as methanol, ethanol and isopropanol), inert solvents (e.g., halogenated hydrocarbon-based solvents such as chloroform, methylene chloride, dichloroethane and carbon tetrachloride, ether-based solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, 1 ,4-dioxane and dimethoxyethane, aprotic solvents such as dimethylformamide, dimethyl sulfoxide, ethyl acetate, tert-butyl acetate, acetonitrile and propionitrile, aromatics such as benzene, toluene and anisole, or hydrocarbons such as cyclohexane),
  • the reaction can be performed at an appropriate temperature selected from a range of from -78°C to the boiling point of the solvent used in the reaction, at ordinary pressure or under pressurized conditions, and under microwave irradiation or the like.
  • a microwave synthesizer Initiator "1" (Biotage) was used for a microwave reaction condition.
  • OH-type silica gel column chromatography was performed using SNAP Ultra (Biotage) or using REVELERIS 40 ⁇ (Grace), and amino-type type silica gel chromatography was performed using SNAPCartridge ISOLUTE Flash-NH 2 (Biotage) or Grace REVELERIS Amino 40 ⁇ (Grace).
  • Preparative chromatography was performed using PLC Silica gel 60F254 (Merck), and amino-type preparative chromatography was performed using NH 2 Silica Gel 60 F 254 Plate- Wako (Wako).
  • the prep-HPLC purifications were performed using Agilent 1260 Infinity or Agilent 6130 (ionization method: Electron Spray Ionization (ESI)), and Agilent 385-ELSD were used when the ELSD detector was attached.
  • Agilent 1260 Infinity or Agilent 6130 ionization method: Electron Spray Ionization (ESI)
  • ESI Electron Spray Ionization
  • a Agilent 1290 Infinity for LC system Agilent 6130 or 6150 for Quadrupole LC/MS system, and Agilent 385-ELSD when a ELSD detector is attached.
  • Ionization method ESI APCI (atmospheric pressure chemical ionization) dual source.
  • Ionization method ESI/APCI (electrospray ionization / atmospheric pressure c hemical ionization) dual source.
  • (+)-CSA (+)-10-camphorsulfonic acid
  • HATU 0-(7-azabenzotriazol- 1 -yl)-N,N,N ⁇ N'-tetramethyluronium hexafluorophosphate HC1: Hydrochloride
  • HMDS Hexamethyldisilazane
  • PEPPSI (l,3-bis(2,6-diisopropylphenyl)imidazolidene)(3-chloropyridyl)palladium(II) dichloride
  • PdCb(dppf) CH2C12 1 , 1 -bi s(diphenylphosphino)ferrocenepalladium(II) chloride dichloromethane complex
  • PdCl 2 (PPh 3 ) 2 Bis(triphenylphosphine)palladium(II) dichloride
  • Pd(PPh 3 ) 4 Tetrakis(triphenylphosphine)palladium(0)
  • T3P Propylphosphonic anhydride
  • TBDPS Tert-butyldiphenylsilyl
  • TBS Tert-butyldimethylsilyl
  • TrCl Triphenylmethyl chloride
  • TsCl 4-Methylbenzenesulfonyl chloride
  • WSC HCl l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
  • Table 1 Reference Compound List. Reference Compound ID, chemical structures, MS data,
  • Reference Compound R-184 3 ⁇ 4 NMR (400 MHz, CHLOROFORM-d) ⁇ ppm 3.43 (s, 3 H), 3.69 - 3.82 (m, 2 H), 3.91 - 3.96 (m, 1 H), 4.11 - 4.19 (m, 1 H), 4.21 - 4.31 (m, 1 H), 6.80 - 6.85 (m, 2 H), 6.94 - 6.97 (m, 1 H), 7.05 (s, 1 H), 7.19 - 7.31 (m, 2 H), 7.50 (s, 1 H).
  • Chemical names of the Reference Compounds in Table- 1 are follows:
  • R-2 N-[l,r-biphenyl]-3-ylglycinamide ⁇ hydrochloride
  • R-3 N-methyl-N-[3-(trifluoromethoxy)phenyl]glycinamide— hydrochloride
  • R-4 N 2 ,N 2 -dimethyl-N- [3 -(trifluoromethoxy)phenyl] glycinamide— hydrochloride
  • R-5 2-(4-ethylpiperazin-l-yl)-N-[3-(trifluoromethoxy)phenyl]acetamide ⁇ hydrochloride
  • R-6 2-(morpholin-4-yl)-N-[3-(trifluoromethoxy)phenyl]acetamide
  • R-7 N- ⁇ 4'- [3 -(morpholin-4-yl)propoxy] [1,1 -biphenyl] -3 -yl ⁇ glycinamide— hydrochloride
  • R-8 3 ,3 ,3-trifluoro-N- [3 -(trifluoromethoxy)phenyl] alaninamide
  • R- 10 N- [3 -(trifluoromethoxy)phenyl] -D-alpha-glutamine— hydrochloride
  • R- 1 1 N- [3 -(trifluoromethoxy)phenyl]-D-histidinamide
  • R-12 3-pyridin-4-yl-N-[3-(trifluoromethoxy)phenyl]-D-alaninamide ⁇ 2 hydrochloride
  • R-13 3-pyridin-3-yl-N-[3-(trifluoromethoxy)phenyl]-D-alaninamide ⁇ 2 hydrochloride
  • R-l 4 N-(4-hydroxypyridin-3-yl)glycinamide— 2 hydrochloride
  • R-l 5 N-(5-bromo-4-hydroxypyridin-3-yl)glycinamide— 2 hydrochloride
  • R-l 7 N-[3-(trifluoromethoxy)phenyl]-D-homoserinamide
  • R-18 2-amino-N 1 -methyl-N 3 -[3-(trifluoromethoxy)phenyl]propanediamide ⁇ hydrochloride
  • R- 19 2-amino-N 1 - [3 -(trifluoromethoxy)phenyl]propanediamide— hydrochloride
  • R-21 (2R)-2-amino-4-[(methanesulfonyl)amino]-N-[3-(trifluoromethoxy)phenyl]butanarnide
  • R-22 3-pyridin-2-yl-N-[3-(trifluoromethoxy)phenyl]-L-alaninamide— 2 hydrochloride
  • R-23 (2R)-2,4-diamino-N-[3-(trifluoromethoxy)phenyl]butanamide
  • R-24 1 - [(O-methyl-3 -oxoseryl)amino] -3 -(trifluoromethoxy)benzene-- hydrochloride
  • R-25 N-(3-bromo-2-propylphenyl)-N-methylglycinamide ⁇ hydrochloride
  • R-28 N 5 -acetyl-N-[3-(trifluoromethoxy)phenyl]-D-ornithinamide
  • R-29 N-(4-hydroxy-5-methoxypyridin-3-yl)glycinamide ⁇ 2 hydrochloride
  • R-32 N-(6-chloro-4-hydroxypyridin-3-yl)glycinamide— 2 hydrochloride
  • R-33 3-acetamido-N-[3-(trifluoromethoxy)phenyl]-D-alaninamide
  • R-34 3 - [(methanesulfonyl)amino] -N- [3 -(trifluoromethoxy)phenyl] -D-alaninamide
  • R-35 N-phenyl-D-serinamide— hydrochloride
  • R-36 N-[3-(trifluoromethoxy)phenyl]-D-lysinamide
  • R-40 l-[(3-oxidanylideneseryl)amino]-3-(trifluoromethoxy)benzene— hydrochloride
  • R-41 N-(5-nitropyridin-2-yl)glycinamide ⁇ 2 hydrochloride
  • R-42 2-amino-2-(pyridin-3-yl)-N-[3-(trifluoromethoxy)phenyl]acetamide ⁇ 2 hydrochloride
  • R-43 N-[3-(propan-2-yl)phenyl]-D-serinamide—trifluoroacetate
  • R-44 3-(l ,3-thiazol-2-yl)-N-[3-(trifluoromethoxy)phenyl]alaninamide ⁇ hydrochloride
  • R-45 N-[4-(trifluoromethoxy)phenyl]-D-serinamide—trifluoroacetate
  • R-48 N-(3-ethoxyphenyl)-D-serinamide—trifluoroacetate
  • R-52 N-[3-(2-phenylethoxy)phenyl]-D-serinamide—trifluoroacetate
  • R-53 N-[3-(hexyloxy)phenyl]-D-serinamide— trifluoroacetate
  • R-54 3-(2-oxo- 1 ,2-dihydroquinolin-4-yl)-N-[3-(trifluoromethoxy)phenyl]alaninamide ⁇ hydrochloride
  • R-56 N-[3-(phenylethynyl)phenyl]-D-serinamide— hydrochloride
  • R-58 N- ⁇ [3-(aminomethyl)phenyl]methyl ⁇ -D-serinamide— 2 hydrochloride .
  • R-62 (2R)-2-amino-3 -hydroxy- 1 - [4-(2-phenylethyl)piperidin- 1 -yljpropan- 1 -one— hydrochloride
  • R-66 N-(5-phenyl-lH-pyrazol-3-yl)-D-serinamide ⁇ hydrochloride
  • R-74 N- [(3 -sulfamoylphenyl)methyl] -D-serinamide— hydrochloride
  • R-75 N-[(4-sulfamoylphenyl)methyl] -D-serinamide— hydrochloride
  • R-76 N-[(4'-amino[l,r-biphenyl]-4-yl)methyl]-D-serinamide— 2 hydrochloride
  • R-77 N- ⁇ [6-(2,2,2-trifluoroethoxy)pyridin-3-yl]methyl ⁇ -D-serinamide— 2 hydrochloride
  • R-78 N-[2-(benzylamino)ethyl]-D-serinamide— 2 hydrochloride
  • R-79 N- ⁇ [2-(2,2,2-trifluoroethoxy)pyridin-3-yl]methyl ⁇ -D-serinamide— 2 hydrochloride
  • R-80 N-[2-hydroxy-2-(3-phenoxyphenyl)ethyl]-D-serinamide— hydrochloride
  • R-82 N-(5-bromopyridin-3-yl)-D-serinamide
  • R-84 3 - [(2,2-difluoroethyl)amino] -N- [3 -(trifluoromethoxy)phenyl] -D-alaninamide
  • R-85 (2R)-2-amino-l -[4-(4-fluorobenzoyl)piperazin-l-yl]-3-hydroxypropan-l-one— hydrochloride
  • R-88 1 -[(4-tert-butylphenyl)methyl]-4-D-serylpiperazin-2-one ⁇ hydrochloride
  • R-93 (2R)-2-amino-3 -hydroxy- 1 -(4-phenoxypiperidin- 1 -yl)propan- 1 -one— hydrochloride
  • R-94 (2R)-2-amino-3 -hydroxy- 1 -(1 'H,2H,4H-spiro[ 1 -benzopyran-3,4'-piperidin]- 1 '- yl)propan-l -one— hydrochloride
  • R-96 (2R)-2-amino-3 -hydroxy- 1 -(3 -phenoxyazetidin- 1 -yl)propan- 1 -one— hydrochloride
  • R-97 N-(2-phenyl-lH-imidazol-4-yl)-D-serinamide
  • R-99 3- ⁇ [2-(methanesulfonyl)ethyl]amino ⁇ -N-[3-(trifluoromethoxy)phenyl]-D-alaninamide
  • R- 100 3 -amino- 1 , 1 -dioxo-N- [3 -(trifluoromethoxy)phenyl] - 1 lambda 6 -thiolane-3 - carboxamide— hydrochloride
  • R-101 S-methyl-N-[3-(trifluoromethoxy)phenyl]-D-cysteinamide
  • R- 102 3 -(methanesulfony 1)-N- [3 -(trifluoromethoxy)phenyl] -D-alaninamide
  • R- 103 N- ⁇ 1 -[(4-chlorophenyl)methyl] - 1 H-pyrazol-3 -yl ⁇ -D-serinamide
  • R-l 04 3-hydroxy-N-[3-(trifluoromethoxy)phenyl]-alpha-asparagine
  • R-105 (2R)-2-amino-3 -hydroxy- l-(4-phenylpiperazin-l-yl)propan-l -one— 2 hydrochloride
  • R- 106 (2R)-2-amino-3 -hydroxy- 1 -(4-phenyl-3,6-dihydropyridin- 1 (2H)-yl)propan- 1 -one— hydrochloride
  • R- 107 (2R)-2-amino- 1 -( 1 ,3 -dihydro-2H-isoindol-2-yl)-3 -hydroxypropan- 1 -one—
  • R- 108 (2R)-2-amino-3 -hydroxy- 1 -(4-phenylpiperidin- 1 -yl)propan- 1 -one— hydrochloride
  • R- 109 (2R)-2-amino-3 -hydroxy- 1 - [(3 S)-3 -phenylpyrrolidin- 1 -yljpropan- 1 -one—
  • R-l 10 (2R)-2-amino-3-hydroxy-l -[(3R)-3-phenylpyrrolidin-l -yljpropan- 1 -one— hydrochloride
  • R-111 (2R)-2-amino-3-hydroxy-l-(l ,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)propan-l-one— hydrochloride
  • R-112 (2R)-2-amino-3 -hydroxy- 1 -(3 -phenylazetidin-l-yl)propan-l -one— hydrochloride
  • R- 1 13 (2R)-2-amino-3 -hydroxy- 1 - [4-(4-methylbenzene- 1 -sulfonyl)piperidin- 1 -yljpropan- 1 - one— hydrochloride
  • R- 1 14 N- 1 H-pyrrolo [3 ,2-b]pyridin-3 -yl-D-serinamide
  • R-116 (2R)-2-amino-l-(4-benzylpiperidin-l-yl)-3 -hydroxypropan- 1 -one— hydrochloride
  • R-117 N- ⁇ 3 - [(naphthalen-2-yl)methoxy]phenyl ⁇ -D-serinamide
  • R-118 N-(2-hydroxyethyl)-N-[3-(propan-2-yl)phenyl]glycinamide
  • R-119 (2R)-2-amino-3-hydroxy-l-[(3S)-3-phenylpiperidin-l-yl]propan-l-one formate
  • R- 120 formic acid— (2R)-2-amino-3 -hydroxy- 1 - [(3R)-3 -phenylpiperidin- 1 -yl]propan- 1 -one formate
  • R-121 N- ⁇ 3-[([l,l'-biphenyl]-4-yl)methoxy]phenyl ⁇ -D-serinamide
  • R-122 glycyl-N-[3-(propan-2-yl)phenyl]glycine ⁇ hydrochloride
  • R-123 N-( 1 -benzyl- 1 H-pyrazol-3-yl)-D-serinamide
  • R- 124 ethyl 3 -hydroxy-N- [3 -(trifluoromethoxy)phenyl] -alpha-asparaginate
  • R-125 N-methyl-N-(3-phenoxypropyl)-D-serinamide— hydrochloride
  • R- 126 N-methyl-N-(4-phenylbutyl)-D-serinamide ⁇ hydrochloride
  • R- 127 2-amino- 1 - ⁇ 4- [(4-methylphenyl)methyl]piperidin- 1 -yl ⁇ ethan- 1 -one
  • R-128 (2R)-2-amino- 1 -(4-benzyl-3,6-dihydropyridin- 1 (2H)-yl)-3 -hydroxypropan- 1 -one
  • R-129 (2R)-2-amino-3-(4-benzylpiperidin-l-yl)-3-oxopropyl
  • R-130 (2R)-2-amino-2-(l,l-dioxo-llambda 6 -thietan-3-yl)-N-[3- (trifluoromethoxy)phenyl]acetamide ⁇ hydrochloride
  • R- 132 (3R)-3-amino- 1 -([ 1 , 1 '-biphenyl]-4-yl)piperidin-2-one ⁇ hydrochloride
  • R- 133 (2R)-2-amino-3 -hydroxy- 1 -(4- ⁇ [3-(phenylethynyl)phenyl]methyl ⁇ piperidin- 1 - yl)propan-l-one— hydrochloride
  • R- 134 (2R)-2-amino- 1 - ⁇ 4- [([ 1 , 1 -biphenyl] -3 -yl)methyl]piperidin- 1 -yl ⁇ -3 -hydroxypropan- 1 - one— hydrochloride
  • R- 135 (2R)-2-amino- 1 -(4-benzyl-4-hydroxypiperidin- 1 -yl)-3-hydroxypropan- 1 -one
  • R- 136 (2R)-2-amino-3 -hydroxy- 1 - ⁇ 4- [hydroxy(phenyl)methyl]piperidin- 1 -yl ⁇ propan- 1 -one
  • R- 137 (2R)-2-amino- 1 -( 1 ,3-dihydro- 1 ⁇ -spiro [indene-2,4'-piperidin]- 1 '-yl)-3- hydroxypropan- 1 -one
  • R- 138 (2R)-2-amino-3 -hydroxy- 1 - [4-(4-methylbenzoyl)piperidin- 1 -yljpropan- 1 -one
  • R-140 N-tl '-biphenylJ-S-yl-D-serinamide
  • R- 141 (2R)-2-amino-3-hydroxy- 1 - ⁇ 4-[(4-methylphenyl)methyl]-3 ,6-dihydropyridin- 1 (2H)- yl ⁇ propan-l-one
  • R- 142 (2R)-2-amino- 1 -(7-bromo-3 ,4-dihydroisoquinolin-2( 1 H)-yl)-3 -hydroxypropan- 1 -one- - hydrochloride
  • R- 143 2-amino-6- [(naphthalen-2-yl)methoxy] -3 ,4-dihydronaphthalen- 1 (2H)-one— hydrochloride
  • R-144 (3S)-3-amino-l-[3-(trifluoromethoxy)phenyl]pyrrolidin-2-one ⁇ hydrochloride
  • R- 145 (3R)-3-amino- 1 -[3-(trifluoromethoxy)phenyl]pyrrolidin-2-one— hydrochloride
  • R-146 (2R)-2-amino-N-(lH-indol-3-yl)-4-(methanesulfonyl)butanamide ⁇ hydrochloride
  • R-147 (3R)-3-amino-l -[3-(benzyloxy)phenyl]pyrrolidin-2-one ⁇ hydrochloride
  • R-148 (3R)-3-amino-l- ⁇ 3-[(4-methylphenoxy)methyl]phenyl ⁇ pyrrolidin-2-one—
  • R-l 49 (2R)-2-amino- 1 -(5-bromo-2,3 -dihydro- 1 H-indol- 1 -yl)-3-hydroxypropan- 1 -one
  • R-l 50 N-[(4-bromophenyl)methyl]-N-methyl-D-serinamide ⁇ hydrochloride
  • R-l 52 3-amino-l-(6-bromopyridin-2-yl)pyrrolidin-2-one ⁇ hydrochloride
  • R-154 formic acid ⁇ (2R)-2-amino-3-hydroxy-l-(4-phenoxy-2,3-dihydro-lH-indol-l- yl)propan-l-one (1/1)
  • R- 155 3-amino- 1 -([ 1 , 1 '-biphenyl]-3-yl)pyrrolidin-2-one
  • R- 156 3-amino-l -[3-(phenylethynyl)phenyl]pyrrolidin-2-one— hydrochloride
  • R- 157 (2R)-2-amino-l -(2,3-dihydro-l H-pyrrolo[2,3-b]pyridin- 1 -yl)-3 -hydroxypropan- 1 -one
  • R- 158 (2R)-2-amino- 1 -(2,3-dihydro- 1 H-pyrrolo [3 ,2-c]pyridin- 1 -yl)-3 -hydroxypropan- 1 -one
  • R- 159 (2R)-2-amino- 1 -(2,3-dihydro- 1 H-pyrrolo[3 ,2-b]pyridin- 1 -yl)-3 -hydroxypropan- 1 -one
  • R- 160 (2R)-2-amino-3 -hydroxy- 1 -(2-phenyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin- 5-yl)propan-l-one ⁇ hydrochloride
  • R-l 61 N-l H-pyrrolo [2,3 -b]pyridin-3-yl-D-serinamide
  • R-162 (2R)-2-amino-3-hydroxy-l-(l-phenyl-l ,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin- 5 -yl)propan- 1 -one
  • R-163 (2R)-2-amino-3-hydroxy-l-(6-hydroxy-2,3-dihydro-lH-indol-l-yl)propan-l-one
  • R- 164 (2R)-2-amino-3 -hydroxy-2-methyl- 1 - ⁇ 4- [(4-methylphenyl)methyl]piperidin- 1 - yl ⁇ propan-l-one
  • R-l 65 2-methyl-N-[3-(propan-2-yl)phenyl]-D-serinamide
  • R- 166 3 -amino-2-hydroxy- 1 - ⁇ 4- [(4-methylpheny l)methyl]piperidin- 1 -yl ⁇ propan- 1 -one
  • R-l 67 (2 R)-2-amino-3 -hydroxy- 1 -(2 -methyl -2, 3 -dihydro- 1 H-indol- 1 -yl)propan-l -one
  • R- 168 (2R)-2-amino-3-hydroxy- 1 -(spiro [cyclobutane- 1 ,3 -indol]- 1 '(2'H)-yl)propan- 1 -one
  • R- 169 (2R)-2-amino- 1 -[3-(2-aminoethyl)-2,3-dihydro- 1 H-indol-1 -yl]-3 -hydroxypropan- 1 - one
  • R-170 N-lH-pyrrolo[3,2-c]pyridin-3-yl-D-serinamide
  • R-171 3-amino-l-[([l,r-biphenyl]-4-yl)methyl]pyrrolidin-2-one
  • R- 172 (2R)-2-amino-3-hydroxy- 1 -( 1 ⁇ -spiro [cyclopropane- 1 ,4'-isoquinolin]-2'(3 ⁇ )- yl)propan-l -one— hydrochloride
  • R-173 N-lH-pyrrolo[2,3-b]pyridin-5-yl-D-alpha-asparagine
  • R- 174 (2R)-2-amino- 1 -(5-bromo- 1 ,3-dihydro-2H-isoindol-2-yl)-3-hydroxypropan- 1 -one
  • R- 175 (2R)-2-amino- 1 -(4-bromo- 1 ,3 -dihydro-2H-isoindol-2-yl)-3 -hydroxypropan- 1 -one
  • R- 176 5 - ⁇ [2-(4-chlorophenyl)ethyl] sulfanyl ⁇ - 1 H-imidazole
  • R-178 N-( ⁇ 4-[(2-phenylethyl)sulfanyl]pyridin-2-yl ⁇ methyl)methanesulfonamide
  • R-l 79 methyl 4- ⁇ [2-([l , 1 '-biphenyl]-4-yl)ethyl]sulfanyl ⁇ pyridine-2-carboxylate
  • R-180 4- ⁇ [2-([l,l'-biphenyl]-4-yl)ethyl]sulfanyl ⁇ pyridine-2-carboxylic acid
  • R-181 l-(lH-imidazol-l-yl)-3-phenoxypropan-2-one
  • R- 182 N-(4-chlorophenyl)-3 -( 1 H-imidazol- 1 -yl)propanamide
  • R- 184 1 -[3-(4-chlorophenoxy)-2-methoxypropyl]- 1 H-imidazole
  • R-l 85 l-(4-chlorophenoxy)-3-(l H-imidazol- l-yl)propan-2-amine
  • R- 186 1 -[2-(4-chlorophenoxy)ethyl]-4-nitro- 1 H-imidazole
  • R-l 87 l-[4-(4-chlorophenyl)butyl]-l H-imidazole
  • R- 192 1 - [3 -(4-chlorophenyl)propyl] - 1 H-imidazol-2 -amine
  • R- 193 1 - [3 -(4-chlorophenyl)propyl] - 1 H-imidazole-2-carboxylic acid
  • R-l 94 ethyl l-[3-(4-chlorophenyl)propyl]-lH-imidazole-2-carboxylate
  • R- 196 1 - [4-(4-chlorophenyl)butyl] - 1 H-imidazole-2-carboxylic acid
  • R- 197 1 -[3-(4-chlorophenyl)propyl]- 1 H-imidazole-2-carboxamide
  • R-l 98 l-[3-(4-chlorophenyl)propyl]-N-methyl-lH-imidazole-2-carboxamide
  • R- 199 4-bromo- 1 - [3 -(4-chlorophenyl)propyl] - 1 H-imidazole
  • R-200 5-bromo- l-[3-(4-chlorophenyl)propyl]-l H-imidazole
  • R-201 1 - [3 -(4-chlorophenyl)propyl] -4-methyl- 1 H-imidazole
  • R-202 methyl 1 - [3 -(4-chlorophenyl)propyl] - 1 H-imidazole-5 -carboxylate
  • R-203 methyl l-[3-(4-chlorophenyl)propyl]-lH-imidazole-4-carboxylate
  • R-204 1 - [3 -(4-chlorophenyl)propyl] - 1 H-imidazole-4-carboxylic acid
  • R-205 1 -[3-(4-chlorophenyl)propyl]- 1 H-imidazole-5-carboxylic acid
  • R-206 3- ⁇ [3-(4-chlorophenyl)propyl]sulfanyl ⁇ -4H-l ,2,4-triazole
  • R-207 l-[3-(4-chlorophenyl)propyl]-lH-imidazol-4-amine ⁇ hydrochloride
  • R-208 l-[3-(4-chlorophenyl)propyl]-5-methyl-lH-imidazole
  • R-209 2-[3-(4-chlorophenyl)propyl]-4-methyl-2,4-dihydro-3H-l,2,4-triazole-3-thione
  • R-210 l-[3-(4-chlorophenyl)propyl]-lH-imidazol-5-amine ⁇ hydrochloride
  • R-21 1 N-( ⁇ l-[3-(4-chlorophenyl)propyl]-lH-imidazol-2-yl ⁇ methyl)-2- (methanesulfonyl)ethan-l -amine
  • R-212 4- ⁇ [2-(4-chlorophenyl)ethyl] sulfanyl ⁇ pyridine-2-carboxylic acid
  • R-213 4- ⁇ [2-(4-chlorophenyl)ethyl]sulfanyl ⁇ pyridine
  • R-214 N- ⁇ 1 -[2-(4-chlorophenoxy)ethyl]- 1 H-imidazol-2-yl ⁇ acetamide
  • R-215 l-[3-(4-chlorophenyl)propyl]-4-fluoro-lH-imidazole
  • R-216 3-hydroxy-5-[(E)-2-phenylethenyl]pyridin-2(lH)-one
  • R-217 3-hydroxy-5-[(2-phenylethyl)sulfanyl]pyridin-2(lH)-one
  • R-218 5- ⁇ [2-(4-chlorophenyl)ethyl] sulfanyl ⁇ -3 -hydro xypyridin-2( 1 H)-one
  • R-219 3-hydroxy-5-[(2-phenoxyethyl)sulfanyl]pyridin-2( 1 H)-one
  • R-220 5-[(2-phenylethyl)sulfanyl]pyridin-2(l H)-one
  • R-221 5- ⁇ [2-([l,l'-biphenyl]-4-yl)ethyl]sulfanyl ⁇ -3-methoxypyridin-2(lH)-one
  • R-222 5- ⁇ [2-([ 1 , 1 '-biphenyl] -4-yl)ethyl] sulfanyl ⁇ -3 -hydroxypyridin-2( 1 H)-one
  • R-224 5- ⁇ [2-(4-chlorophenyl)ethyl] sulfanyl ⁇ -2-ethoxy-3 -methoxypyridine
  • R-225 5- ⁇ [2-(4-chlorophenyl)ethyl] sulfanyl ⁇ -3 -methoxypyridin-2( 1 H)-one
  • R-226 5- ⁇ [2-(4-chlorophenyl)ethyl]sulfanyl ⁇ pyridin-2(lH)-one
  • R-227 5- ⁇ [2-(4-chlorophenyl)ethyl] sulfanyl ⁇ -3 -methoxypyrazin-2( 1 H)-one
  • R-228 5-[(3-fluorophenyl)sulfanyl]-3-hydroxypyridin-2(lH)-one
  • R-229 5- ⁇ [2-(4-chlorophenyl)ethyl] sulfanyl ⁇ - 1 ,4-dihydropyrazine-2,3 -dione
  • R-230 5 - [(3-chloro-5 -fluorophenyl)sulfanyl]-3 -hydroxypyridin-2( 1 H)-one
  • R-231 4- ⁇ [2-(4-chlorophenyl)ethyl]sulfanyl ⁇ thieno[2,3-c]pyridin-7(6H)-one
  • R-233 4- ⁇ [2-(4-chlorophenyl)ethyl] sulfanyl ⁇ -7-methoxy- 1 H-pyrrolo [2,3 -c]pyridine
  • R-234 3-chloro-5- ⁇ [2-(4-chlorophenyl)ethyl]sulfanyl ⁇ pyridin-2(lH)-one
  • R-235 4- ⁇ [2-(4-chlorophenyl)ethyl] sulfanyl ⁇ - 1 ,6-dihydro-7H-pyrrolo [2,3 -c]pyridin-7-one
  • R-236 5 - [(3 -fluoro-5-propoxyphenyl)sulfanyl] -3 -hydroxypyridin-2( 1 H)-one
  • R-237 5- ⁇ [2-(3 -chloropheny l)ethyl] sulfanyl ⁇ -3 -hydroxypyridin-2( 1 H)-one
  • R-238 5-[(4-chlorophenyl)sulfanyl]-3-hydroxypyridin-2( 1 H)-one
  • R-239 5- ⁇ [2-(4-chlorophenyl)ethyl] sulfanyl ⁇ -2-oxo- 1 ,2-dihydropyridine-3 -carboxylic acid
  • R-240 5- ⁇ [2-(4-chlorophenyl)ethyl] sulfanyl ⁇ -3 -(hydroxymethyl)pyridin-2( 1 H)-one
  • R-243 5-( ⁇ 2-[4-(benzyloxy)phenyl]ethyl ⁇ sulfanyl)-3-hydroxypyridin-2(lH)-one
  • R-244 5-[2-(4-chlorophenyl)ethanesulfonyl]-3-hydroxypyridin-2(l H)-one
  • R-245 3-hydroxy-5- ⁇ [2-(4-hydroxyphenyl)ethyl]sulfanyl ⁇ pyridin-2(lH)-one
  • R-246 3-hydroxy-5-( ⁇ 3 - [4-(phenylethynyl)phenyl]propyl ⁇ sulfanyl)pyridin-2( 1 H)-one
  • R-247 5 - ⁇ [3 - ( [ 1 , l'-biphenyl] -4-yl)propyl] sulfanyl ⁇ -3 -hydroxypyridin-2( 1 H)-one
  • R-248 3-hydroxy-5-( ⁇ 2-[4-(phenylethynyl)phenyl]ethyl ⁇ sulfanyl)pyridin-2(lH)-one
  • R-249 3-hydroxy-5-( ⁇ 3-[4-(2-phenylethyl)phenyl]propyl ⁇ sulfanyl)pyridin-2(l H)-one
  • R-250 3-hydroxy-5- ⁇ [5-(pyridin-4-yl)-4H-l ,2,4-triazol-3-yl]sulfanyl ⁇ pyridin-2(lH)-one
  • R-251 3-hydroxy-5-[(4- ⁇ [4-(3-hydroxypropyl)phenyl]ethynyl ⁇ phenyl)sulfanyl]pyridin- 2(lH)-one
  • R-252 5- ⁇ [2-(4-chlorophenyl)ethyl]sulfanyl ⁇ -4-fluoro-3-hydroxypyridin-2(lH)-one
  • R-256 5- ⁇ [3 -(4-chlorophenyl)- 1 H-1 ,2,4-triazol- 1 -yljmethyl ⁇ -3 -hydroxypyridin-2( 1 H)-one
  • R-257 [4-(4-chlorophenyl)butyl]propanedioic acid
  • R-258 2-(4-chlorophenyl)-5 - ⁇ [(4H- 1 ,2,4-triazol-3 -yl)sulfanyl]methyl ⁇ - 1 ,3 ,4-oxadiazole
  • R-259 2-(lH-pyrrol-l-yl)benzoic acid
  • R-260 (3-ethyl-l,2,4-oxadiazol-5-yl)methyl carbamimidothioate— hydrochloride
  • R-261 5- ⁇ [4-(4-chlorophenyl)-l,2,3-triazol-l-yl]methyl ⁇ -3-hydroxy-lH-pyridin-2-one
  • R-262 (E)-5-(3 -(4-chlorophenyl)prop- 1 -en- 1 -yl)-3 -hydroxypyridin-2( 1 H)-one
  • R-263 (E)-5-(2-(4-chlorophenyl)prop- 1 -en- 1 -yl)-3-hydroxypyridin-2(l H)-one
  • reaction mixture was allowed to warm to room temperature, stirred further 3 hours, quenched with a saturated aqueous sodium bicarbonate and extracted with CHC1 3 three times.
  • the organic layer was passed through a phase separator and concentrated in vacuo onto ISOLUTE® HM-N.
  • the residue was purified with OH-type silica gel column chromatography (8-31 % EtOAc in n-hexane) to give the title compound (1.2 g, 15 % yield) as a yellow oil.
  • triphenylphosphine (0.18 g), hexamethyldisilazane (0.52 mL) and triethylamine (1.7 g) in DMF (8.4 mL) was evacuated and backfilled with nitrogen three times. The mixture was stirred for 10 minutes at 1 10 °C. 2-[2-(4-Ethynylphenoxy)ethoxy]tetrahydropyran (0.83 g). was added into the mixture. The reaction mixture was stirred for 5 hours at 110 °C and overnight at room temperature, quenched with water and extracted with EtOAc. The organic layer was washed with water twice, dried over MgS0 4 , filtered and concentrated in vacuo.
  • tert-butyl 3-oxopyrrolidine-l- carboxylate (0.15 g) in THF was added into the mixture.
  • the reaction mixture was allowed to warm to room temperature and stirred further 2 hours.
  • the mixture was quenched with a saturated aqueous sodium bicarbonate and extracted three times with CHCI3.
  • the organic layer was passed through a phase separator and concentrated in vacuo onto ISOLUTE® HM- N.
  • Example Compounds in Table 2 and Table 3 were obtained in a manner as with above experimental procedures or general procedures using the corresponding materials.
  • Example Compounds (Compound- 1 to Compound-33). Compound ID, chemical structures, 'H-NMR data, MS data and LCMS retention time (minutes) data are shown.
  • Test 1 Evaluation of the inhibitory activities on Pseudomonas aeruginosa LpxC enzyme Inhibitory activities on P. aeruginosa LpxC enzyme of compounds were evaluated using the following LCMS method.
  • LpxC was reacted with its substrate UDP-3-0-(R-3-hydroxydecanoyl)-N-acetylglucosamine.
  • the amounts of substrate and reacted product were determined with a liquid chromatography-tandem mass spectrometry (LC/MS/MS).
  • LC/MS/MS liquid chromatography-tandem mass spectrometry
  • aeruginosa LpxC genes incorporating the genes into a vector, and expressing in Escherichia coli
  • UDP-3-0-(R-3 -hydroxy decanoyl)-N-acetylglucosamine Alberta Research Council
  • the reaction was performed in 40 mmol/L of Hepes buffer solution (pH 8.0) supplemented with 0.02% (v/v) Brij 35 and 25 nmol/L of ZnCl 2 .
  • acetonitrile containing 25 ⁇ /L of UDP-GlcNAc as internal standard was added.
  • the mixture was centrifuged and supernatant was injected into LC/MS/MS.
  • the samples were separated with Inertsil Amide (3.0 ⁇ , 50 mm x 2.1 mm I.D., GLScience, Japan).
  • the mobile phase was 8 mmol/L ammonium acetate containing 72% acetonitrile and flow rate was 0.2mL/min.
  • MS/MS detection of each component was performed using a TSQ Quantum system with electrospray interface (ThermoFisher Scientific, USA) in negative ion detection mode.
  • An inhibition curve was constructed for each test compound by performing the aforementioned reaction at varying concentrations of the test compound. From this inhibition curve, the concentration of the test compound at which the formation of the reaction product was suppressed by 50% was determined as the IC 50 of the test compound, which was an index for the inhibitory activity on P. aeruginosa LpxC enzyme.
  • the present invention enables providing novel compounds that inhibit LpxC or

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés représentés par la formule générale suivante [1] ou des sels pharmaceutiquement acceptables de ceux-ci, qui inhibent la LpxC, ainsi que des médicaments pharmaceutiques comprenant ces composés ou des sels pharmaceutiquement acceptables de ceux-ci, qui présentent une activité antimicrobienne contre des bactéries à Gram-négatif comprenant Pseudomonas aeruginosa et leurs souches résistantes aux médicaments et sont utiles dans le traitement d'infections bactériennes, dans la formule, X est choisi parmi la formule suivante [2] : Y est choisi parmi la formule suivante [3].
PCT/JP2018/021101 2017-05-25 2018-05-25 Dérivés d'alpha-amino-amide WO2018216823A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1708390.8A GB2562777A (en) 2017-05-25 2017-05-25 Novel alpha-amino amide derivatives
GB1708390.8 2017-05-25

Publications (1)

Publication Number Publication Date
WO2018216823A1 true WO2018216823A1 (fr) 2018-11-29

Family

ID=59271060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/021101 WO2018216823A1 (fr) 2017-05-25 2018-05-25 Dérivés d'alpha-amino-amide

Country Status (2)

Country Link
GB (1) GB2562777A (fr)
WO (1) WO2018216823A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111187218A (zh) * 2020-02-26 2020-05-22 四川大学 1-取代-1H-咪唑-2-羧酸类化合物在制备金属β-内酰胺酶抑制剂中的用途
CN111253317A (zh) * 2020-02-26 2020-06-09 四川大学 一种1-取代-1h-咪唑-2-羧酸类化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027466A1 (fr) * 2006-08-31 2008-03-06 Schering Corporation Derives d'hydantoine utiles en tant qu'agents antibacteriens
WO2015024016A2 (fr) * 2013-08-16 2015-02-19 Duke University N,3-dihydroxybutanamides substitués par 2-pipéridinyle
WO2015085238A1 (fr) * 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibiteurs de lpxc

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2307365B1 (fr) * 2008-06-25 2013-03-27 Merck Sharp & Dohme Corp. Synthèse et utilisation d agents antibactériens hétérocycliques
WO2010100475A1 (fr) * 2009-03-02 2010-09-10 Astrazeneca Ab Dérivés de l'acide hydroxamique en tant qu'agents contre des bactéries à gram négatif
WO2013170165A1 (fr) * 2012-05-10 2013-11-14 Achaogen, Inc. Agents antibactériens

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027466A1 (fr) * 2006-08-31 2008-03-06 Schering Corporation Derives d'hydantoine utiles en tant qu'agents antibacteriens
WO2015024016A2 (fr) * 2013-08-16 2015-02-19 Duke University N,3-dihydroxybutanamides substitués par 2-pipéridinyle
WO2015085238A1 (fr) * 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibiteurs de lpxc

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem Compound [online] NCBI; 10 December 2015 (2015-12-10), XP002783890, Database accession no. CID 93255515 *
DATABASE PubChem Compound [online] NCBI; 10 December 2015 (2015-12-10), XP002783891, Database accession no. CID 93255514 *
DATABASE PubChem Compound [online] NCBI; 13 January 2016 (2016-01-13), XP002783889, Database accession no. CID 103793796 *
DATABASE PubChem Compound [online] NCBI; 15 January 2016 (2016-01-15), XP002783888, Database accession no. CID 107569415 *
DATABASE PubChem Compound [online] NCBI; 15 June 2016 (2016-06-15), XP002783887, Database accession no. CID 119278459 *
DATABASE PubChem Compound [online] NCBI; 19 October 2012 (2012-10-19), XP002783893, Database accession no. CID 61369680 *
DATABASE PubChem Compound [online] NCBI; 21 July 2009 (2009-07-21), XP002783894, Database accession no. CID 43650160 *
DATABASE PubChem Compound [online] NCBI; 23 October 2012 (2012-10-23), XP002783892, Database accession no. CID 64894681 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 11 April 2010 (2010-04-11), XP002783905, Database accession no. 1218176-49-8 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 13 April 2014 (2014-04-13), XP002783902, Database accession no. 1583749-66-9 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 13 June 2011 (2011-06-13), XP002783903, Database accession no. 1309019-85-9 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 19 May 2014 (2014-05-19), XP002783900, Database accession no. 1606869-65-1 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 21 April 2014 (2014-04-21), XP002783901, Database accession no. 1587535-60-1 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 27 December 2015 (2015-12-27), XP002783896, Database accession no. 1837399-88-8 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 27 December 2015 (2015-12-27), XP002783897, Database accession no. 1837399-87-7 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 27 December 2015 (2015-12-27), XP002783898, Database accession no. 1837365-39-5 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 27 December 2015 (2015-12-27), XP002783899, Database accession no. 1837365-38-4 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 31 May 2016 (2016-05-31), XP002783895, Database accession no. 1921463-32-2 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 6 May 2011 (2011-05-06), XP002783904, Database accession no. 1290756-76-1 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111187218A (zh) * 2020-02-26 2020-05-22 四川大学 1-取代-1H-咪唑-2-羧酸类化合物在制备金属β-内酰胺酶抑制剂中的用途
CN111253317A (zh) * 2020-02-26 2020-06-09 四川大学 一种1-取代-1h-咪唑-2-羧酸类化合物
CN111253317B (zh) * 2020-02-26 2023-08-04 四川大学 一种1-取代-1h-咪唑-2-羧酸类化合物
CN111187218B (zh) * 2020-02-26 2023-08-04 四川大学 1-取代-1H-咪唑-2-羧酸类化合物在制备金属β-内酰胺酶抑制剂中的用途

Also Published As

Publication number Publication date
GB201708390D0 (en) 2017-07-12
GB2562777A (en) 2018-11-28

Similar Documents

Publication Publication Date Title
ES2648228T3 (es) Derivados de imidazo[1,2-b]piridazina como inhibidores de cinasa
IL255960A (en) Disubstituted heterocyclyl derivatives as inhibitors of cyclin-dependent kinases
AU2008235456B2 (en) [2, 6] naphthyridines useful as protein kinase inhibitors
JP6986653B2 (ja) ケトヘキソキナーゼ阻害剤としての二置換ピラゾール化合物
CN111683662A (zh) 取代嘧啶类化合物及其药物组合物和治疗方法
KR20190133199A (ko) 브루톤 타이로신 키나제 억제제
TW202208379A (zh) 新穎的巨環lrrk2激酶抑制劑
WO2018216823A1 (fr) Dérivés d'alpha-amino-amide
CN110655520A (zh) 嘧啶并环化合物及其制备方法和应用
JP5602161B2 (ja) ホスフィナートルテニウム錯体
WO2023060362A1 (fr) Inhibiteurs de ras, compositions et procédés d'utilisation de ceux-ci
CN117897380A (zh) 哒嗪酮或吡啶酮化合物、其制备方法和用途
CA2919297C (fr) Derives piperidine et azepine servant de modulateurs du recepteur de la prokineticine
CN112521372B (zh) 一种细胞凋亡蛋白抑制剂及其制备方法和用途
Hong et al. Discovery of PIM Kinase Inhibitor: 1, 3, 4-oxadiazole-2 (3H)-thione Analogs
TW202229275A (zh) 自分泌運動因子(autotaxin)抑制劑化合物
JP2023514364A (ja) Ｍｃｌ－１の阻害剤としての大環状インドール誘導体
CN117677616A (zh) 制备血红蛋白调节剂的方法
EP3074385A1 (fr) Dérivés de pipéridine destinés à être utilisés dans le traitement ou la prévention de troubles psychiatriques et neurologiques
EA043635B1 (ru) Дизамещенные пиразольные соединения в качестве ингибиторов кетогексокиназы

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18739654

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18739654

Country of ref document: EP

Kind code of ref document: A1